A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis

Journal of Clinical Apheresis

Volumn 26, Issue 6, 2011, Pages 347-355

  Köhler, Wolfgang ^a   Bucka, Christoph ^a   Klingel, Reinhard ^b  

^a Fachkrankenhaus Hubertusburg ^*  (Germany)

^b Apheresis Research Institute   (Germany)

Author keywords

Immunoadsorption; Myasthenia gravis; Myasthenic crisis; Plasma exchange; Therapeutic apheresis

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; PYRIDOSTIGMINE;

ADULT; AGED; ARTICLE; BACKACHE; BLEEDING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYSTITIS; DISEASE COURSE; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMATOMA; HUMAN; HYPERSALIVATION; HYPOKALEMIA; IMMUNOADSORPTION; MALAISE; MALE; MYASTHENIA; MYASTHENIA GRAVIS; PLASMAPHERESIS; PNEUMONIA; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SAFETY; SHOCK; TACHYCARDIA; TREATMENT OUTCOME;

AGED; AUTOANTIBODIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PLASMA EXCHANGE; PROSPECTIVE STUDIES; RECEPTORS, NICOTINIC; TREATMENT OUTCOME;

EID: 83555162439     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20317     Document Type: Article

References (43)

1. Jani-Acsadi A, Lisak RP,. Myasthenia gravis. Curr treat Options Neurol 2010; 12: 231-243.
2. Koehler W, Sieb JP,. Myasthenia Gravis, 3rd ed. Germany: UniMed Publishers Bremen; 2008.
3. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW,. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902.
4. Oopik M, Kaasik AE, Jakobsen J,. A population based epidemiological study on myasthenia gravis in Estonia. J Neurol Neurosurg Psychiatry 2003; 74: 1638-1643. (Pubitemid 37542051)
5. Poulas K, Tsibri E, Kokla A, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T, Tzartos SJ,. Epidemiology of seropositive myasthenia gravis in Greece. J Neurol Neurosurg Psychiatry 2001; 71: 352-356. (Pubitemid 32772533)
6. Farrugia M, Vincent A,. Autoimmune mediated neuromuscular junction defects. Curr Opinion Neurol 2010; 23: 489-495.
7. Thanvi BR, Lo TCN,. Update on myasthenia gravis. Postgrad Med J 2004; 80: 690-700. (Pubitemid 39627099)
8. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E,. Clinical correlates with anti MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126: 2304-2311. (Pubitemid 37432373)
9. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A,. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-368. (Pubitemid 32224355)
10. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A,. Clinical aspects of MuSK antibody positive seronegative myasthenia gravis (SNMG). Neurology 2003; 60: 1978-1980. (Pubitemid 36736017)
11. Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, Provenzano C, Bartoccioni E,. Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002; 82: 1139-1146. (Pubitemid 35014847)
12. Chaudhuri A, Behan PD,. Myasthenic crisis. QJM 2009; 102: 97-107.
13. Lacomis D,. Myasthenic crisis. Neurocrit Care 2005; 3: 189-194. (Pubitemid 43004811)
14. Juel VC,. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 2004; 24: 75-81. (Pubitemid 38823781)
15. Thomas CE, Mayer SA, Gungor Y,. Myasthenic crisi: clinical features, mortality, complications and risk factors for prolonged intubation. Neurology 1997; 48: 1253-1260. (Pubitemid 27240543)
16. Mayer SA,. Intensive care of the myasthenic patient. Neurology 1997; 48: S70-S75. (Pubitemid 27174924)
17. Gold R, Schneider-Gold C,. Current and future standards in the treatment of myasthenia gravis. Neurotherapeutics 2008; 5: 535-541.
18. Gold R, Krenzer M, Klinker E, Mansouri B, Schneider-Gold C, Müllges W, Boeck M, Toyka KV,. Efficacy and safety of immunoadsorption vs plasmapheresis vs combination for treatment of myasthenic crisis: comparative retrospective study on 72 Patients. American Acad Neurol 2008 annual meeting abstracts. Available at: http://www.abstracts2view.com/aan2008chicago.
19. Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D,. Therapy of myasthenic crisis. Crit Care Med 1997; 25: 1228-1235. (Pubitemid 27310266)
20. Splendiani G, Passalacqua S, Barbera G, Sturniolo A, Costanzi S, Bartoccioni E, Casciani CU,. MG treatment with immunoadsorbent column. Biomater Artif Cells Immobilization Biotechnol 1991; 19: 255-265.
21. Haupt WF, Rosenow F, van der Ven C, Birkmann C,. Immunoadsorption in Guillian-Barré syndrome and Maysthenia gravis. Ther Apher 2000; 4: 195-197. (Pubitemid 30445870)
22. Ishizeki J, Nishikawa K, Kunimoto F, Goto F,. Postoperative myasthenic crisis successfully treated with immunoadsorption therapy. J Anesth 2005; 19: 320-322. (Pubitemid 41662542)
23. Wanieski J, Wernyski A,. Mathematical modelling of antigen and immune complex kinetics during extracorporeal removal of autoantibody. Int J Artif Organs 1991; 14: 186-188.
24. Bucka C, Köhler W, Hertel G, Voigt W, Bennhold I, Schimrigk S, Lange R,. Immunoadsorption in Myasthenia Gravis. Mechanisms of action, immunological markers and clinical course. Akt Neurol 1993; 20: 207-213. (Pubitemid 24019092)
25. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC,. Plasma exchange in neuroimmunological disorders. II. Treatment of neuromuscular disorders. Arch Neurol 2006; 63: 1066-1071. (Pubitemid 44232310)
26. Chiu H-C, Chen W-H, Yeh J-H,. The six year experience of plasmapheresis on patients with Myasthenia gravis. Ther Apher 2000; 4: 291-295.
27. Yeh J-H, Chiu H-W,. Comparison between double filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000; 247: 510-513. (Pubitemid 30598876)
28. Oosterhuis HJ,. The natural course of myasthenia gravis: a long term follow-up study. J Neurol Neurosurg Psychiatry 1989; 52: 1121-1127. (Pubitemid 19255673)
29. Antozzi C, Gemma M, Regi B, Berta E, Confalonieri P, Peluchetti D, Mategazza R, Baggi F, Marconi M, Fiacchino F, Cornelio F,. A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol 1991; 238: 103-107.
30. Trikha I, Singh S, Goyal V, Shukla G, Bhasin R, Behari M,. Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis. J Neurol 2007; 254: 989-995. (Pubitemid 47353400)
31. Grob D, Simpson D, Mitsumoto H, Hoch B, Mokhtarian F, Bender A, Greenberg M, Koo A, Nakayama S,. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995; 45: 338-344.
32. Hirata N, Kuriyama T, Yamawaki N,. Immusorba TR and PH. Therapeutic Apheresis Dialysis 2003; 7: 85-90. (Pubitemid 36648049)
33. Shibuya N, Sato T, Osame M, Takegami T, Doi S, Kawanami S,. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994; 57: 578-581. (Pubitemid 24151250)
34. Goldammer A, Derfler K, Herkner K, Bradwell AR, Hoerl W, Haas M,. Influence of plasma immunoglobulin level on antibody synthesis. Blood 2002; 100: 353-355. (Pubitemid 35177470)
35. Kornfeld P, Ambinder EP, Mittag T, Bender AN, Papatestas AE, Goldberg J, Genkins G,. Plasmapheresis in refractory generalized myasthenia gravis. Arch Neurol 1981; 38: 478-481. (Pubitemid 11046563)
36. Nielsen VK, Paulson OB, Rosenkvist J, HolsÃμe E, Lefvert AK,. Rapid improvement of myasthenia gravis after plasma exchange. Ann Neurol 1981; 11: 160-169.
37. Heininger K, Immunoadsorption via hydrophobic interaction: a new therapeutic concept in MG and CIDP. Ther Plasmapheresis 1998; VIII: 5-16.
38. Wagner S, Janzen RWC, Mohs C, Pohlmann S, Klingel R, Grützmacher PW,. Long-term treatment of refractory myasthenia gravis with immunoadsorption. Dtsch Med Wochenschr 2008; 133: 2377-2382.
39. Cruz J, Skipworth E, Blue D, Waxman D, McCarthy L, Smith D,. Transfusion-related acute lung injury: a thrombotic thrombocytopenic purpura treatment-associated case report and concise review. J Clin Apheresis 2008; 23: 96-103. (Pubitemid 351656261)
40. Nagai Y, Itabashi M, Mizutani M, Ogawa T, Yumura W, Tsuchiya K, Nitta K,. A case report of uncompensated alkalosis induced by daily plasmapheresis in a patient with thrombotic thrombocytopenic purpura. Ther Apher Dialysis 2008; 12: 86-90. (Pubitemid 351197459)
41. Galldiks N, Dohmen C, Neveling M, Fink GR, Haupt WF,. Selective immune adsorption treatment of severe Guillain Barre' syndrome in the Intensive care unit. Neurocrit Care 2009; 11: 317-321.
42. Schroeder A, Linker RA, Gold R,. Plasmapheresis for neurological disorders. Expert Rev Neurother 2009; 9: 1331-1339.
43. Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A,. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease activity. Neurology 1983; 33: 1316-1321. (Pubitemid 13021194)